merger announcement, page-4

On the contrary, as an EGX holder I'm disappointed (naturally of course) that we're not getting a higher bid.

Given the recent acquisitions in the antibody field:

�� Feb 06 – Abgenix acquired by Amgen – US$2,200 million
�� May 06 – Cambridge Antibody Technology acquired by Astra Zeneca –
US$1,300 million
�� July 06 – Amrad/Zenyth acquired by CSL - A$108 million
�� Dec 06 - Domantis acquired by GSK – US$454 million
�� April 07 – Morphotek acquired by Eisai – US$325 million

I don't know enough to compare EGX to the above but it must be comparable to Amrad/Zenyth.